About Coherus

Leadership Team

Members of the team leading Coherus include pioneers of top-selling biologic drugs – the first fruit of the biotech revolution. Today, they’re shaping the coming era of biosimilar innovation.

In life sciences, experience matters. That’s because cell manipulation, whether under a microscope or at full manufacturing scale, is an art as much as a science. Some members of our team helped set industry standards for process development, protein manufacturing and analytical research at organizations that unleashed the first wave of biologics. Together and individually, they worked on 100 molecules; developed and manufactured more than 14 licensed products, and launched more than 30 products in the U.S. and around the world.

  • DENNIS M. LANFEAR

    PRESIDENT, CEO & CHAIRMAN

    • DENNIS M.
      LANFEAR

      PRESIDENT, CEO & CHAIRMAN

      Industry Experience

      32

      Years

      Prior Experience

      Amgen, Baxter

      Dennis Lanfear is a biotechnology pioneer and leader with a track record for entrepreneurial vision and achievement. He founded Coherus Biosciences in 2010, assuming the roles of President, CEO and Chairman, and quickly turned the company from a startup into the industry’s leading “pure play” in biosimilar drugs. Having recruited some of biotech’s most accomplished drug developers, Coherus has built a late stage pipeline of biosimilar treatments for inflammatory diseases and cancer. The team Mr. Lanfear put together is now delivering on its vision of improved access to high quality, life-changing medicines. Coherus is backed by more than $400M in capital raised from the public and private markets. This includes over $110M in net proceeds from an April 2015 follow-on public offering, over $80M in net proceeds from a November 2014 IPO, and over $220M in private financing. Collaborations with Daiichi Sankyo and Baxter International further strengthen the company’s global drug development agenda.

      Mr. Lanfear has nearly 30 years of biopharmaceutical business experience in technical and leadership roles. He is a 13-year veteran of Amgen, where he served as a Vice President with broad operational, product development and marketing responsibility. He spent 10 of those years running Amgen’s renowned Process Development Department, where he was tasked with integrating more than 2,500 operations and staff worldwide. Mr. Lanfear spearheaded multiple development programs for growth factors, somatotropins and neurotrophins, taking these products from preclinical to Phase 3. He reviewed and wrote sections of more than 20 INDs and several BLAs, and he had direct budgetary responsibility for the $135 million development partnership with Regeneron Pharmaceuticals from 1991 to 1999. In 1997 Mr. Lanfear was named Amgen’s Vice President, Market Development. In this role, he defined long term competitive and reimbursement strategies for Epogen®, a multibillion dollar drug.

      Prior to joining Amgen, Mr. Lanfear held positions at Baxter International and was also the founder and CEO of Saronyx, Inc., a drug development software services company. In 2005, he founded InteKrin Therapeutics, serving as President, CEO, and Chairman in 2010. He is an investor in and former director of Anthera Pharmaceuticals, and a former director of Insmed Therapeutics. Mr. Lanfear holds biochemistry and chemical engineering degrees from Michigan State University and an MBA from the Anderson School at UCLA.

  • BARBARA K. FINCK, M.D.

    CHIEF MEDICAL OFFICER

    • BARBARA K.
      FINCK, M.D.

      CHIEF MEDICAL OFFICER

      Industry Experience

      20

      Years

      Prior Experience

      Immunex, PDL Biopharma, Osprey Pharmaceuticals, NKT Therapeutics

      Dr. Finck is a board certified rheumatologist with more than 20 years of preclinical and clinical drug development experience in academic and biopharmaceutical settings. She received her rheumatology training at University of California, San Francisco, where she studied the effects of CTLA4-Ig (subsequently developed and marketed as Orencia®) in a murine lupus nephritis model. Dr. Finck, whose drug development activities have spanned multiple therapeutic areas, started her pharmaceutical career at ALZA as medical director for early clinical development of Ditropan-XL®, to treat spasms of the bladder. She subsequently held senior level positions at a half-dozen innovative biopharmaceutical companies. At Immunex (later acquired by Amgen) she was lead medical director for the Phase III clinical development of Enbrel® in rheumatoid arthritis and juvenile idiopathic arthritis. At Eos Biotechology, she was VP for Clinical Development. In addition, she was on the executive teams at PDL Biopharma (VP, Clinical Development), Osprey Pharmaceuticals USA, Inc. (Senior VP, Research and Development, and Chief Medical Officer), and NKT Therapeutics, Inc. (Chief Medical Officer). Throughout her career in pharmaceutical development, Dr. Finck has demonstrated the ability to build effective teams and alliances, as well as a personal passion for developing therapeutics to treat diseases where there is significant unmet medical need.

  • ALAN HERMAN, PH.D.

    CHIEF SCIENTIFIC OFFICER

    • ALAN
      HERMAN, PH.D.

      CHIEF SCIENTIFIC OFFICER

      Industry Experience

      32

      Years

      Prior Experience

      Genentech, Amgen, Merck

      Dr. Herman has more than 32 years of experience at some of the most significant companies in the biopharmaceutical space. He started his career at Merck, working on recombinant hepatitis B vaccine. Later, at Genentech, he focused on process development and pharmaceutics, contributing to the development of human growth hormone, tissue plasminogen activator, and interferon. At Amgen, he started the Analytical Research and Development Department, which he managed for 11 years. The cutting-edge analytics that emerged from this effort significantly contributed to radical changes in the regulatory review of recombinant products, leading to the “well defined biological products” characterization that enabled more rapid product development. This work helped lay the groundwork for biosimilar products in regulated markets.

      During Dr. Herman’s tenure at Amgen, his department contributed to more than 20 INDs and several BLAs. In 2003, he became Senior Director of Quality Control for Tercica, Inc., a start-up that in-licensed a late-stage compound (IGF-1) from Genentech. His group designed a comparability program that would minimize the need for further clinical trials. Dr. Herman also supervised contract laboratories in areas such as product characterization, method development and validation, release testing, and clinical and commercial stability. Dr. Herman served as CSO and Vice President of Product Development at Althea until 2011, when he joined Coherus Biosciences.

      Dr. Herman holds B.S. and M.S. degrees in biology from Indiana University of Pennsylvania and a Ph.D. in protein chemistry from Duke University.

  • JEAN-FREDERIC VIRET, PH.D.

    CHIEF FINANCIAL OFFICER

    • JEAN-FREDERIC
      VIRET, PH.D.

      CHIEF FINANCIAL OFFICER

      Industry Experience

      22

      Years

      Prior Experience

      Anesiva, Corgentech, Tularik

      Dr. Viret, a Ph.D. plant molecular biologist by training, has worked for approximately two decades in corporate finance within the life sciences industry. Before joining Coherus as Chief Financial Officer in September 2014, he held the title of CFO at diaDexus, Inc., a cardiovascular diagnostics company, at CareDx, Inc. (formerly XDx, Inc.), a molecular diagnostics company, and at Anesiva, Inc., a biopharmaceutical company. Prior, he worked in finance at Tulark, and business assurance services at PricewaterhouseCoopers LLP.

      In addition to a Ph.D. in Plant Molecular Biology from Université Louis Pasteur (Strasbourg), Dr. Viret has a B.S. in Engineering from the Institut National Polytechnique de Lorraine and an M.B.A. from Cornell University. He was a visiting fellow at Harvard University and a postdoctoral fellow at the Massachusetts Institute of Technology.

  • PETER WATLER, PH.D.

    CHIEF TECHNICAL OFFICER

    • PETER
      WATLER, PH.D.

      CHIEF TECHNICAL OFFICER

      Industry Experience

      32

      Years

      Prior Experience

      Amgen, Hyde, VaxGen

      Dr. Watler has more than 32 years of biopharmaceutical process development and manufacturing experience, including 12 years at Amgen. He has deep knowledge of the development and scale-up of biopharmaceutical processes such as fermentation, centrifugation, filtration, and chromatography. His skill set spans process modeling, economic analysis, manufacturing operational excellence, process control and validation. His regulatory experience includes co-authoring two IND submissions, four BLA submissions, and participation in several FDA inspections and GMP audits.

      As Amgen’s Associate Director of Process Engineering, he oversaw the launch of a 30,000 square foot pilot plant for monoclonal antibody development, managing scale up from the laboratory through clinical production for more than ten product candidates. He also led teams responsible for the process validation of Neupogen®, Stemgen®, Kepivance® and Infergen®. Dr. Watler most recently served as Chief Technology Officer of Hyde Engineering + Consulting, Inc. He led projects for GMP manufacturing facility design, implementing state-of-the-art technologies to drive down capital costs while enhancing cGMP compliance and operational efficiency. Dr. Watler was previously Vice President, Manufacturing at VaxGen, a Genenetech spinoff formed to develop an AIDS vaccine.

      Dr. Watler has presented extensively in the US, Canada, China, Europe and Japan on the latest ICH, FDA and ASTM approaches to pharmaceutical risk management, process validation and Quality by Design. He holds Bachelor and Masters degrees in Chemical Engineering from the University of Toronto and a Ph.D. in Chemical Engineering from Yamaguchi University, Japan.

  • VINCE ANICETTI

    SVP, Quality and Compliance

    • VINCE
      ANICETTI

      SVP, Quality and Compliance

      Industry Experience

      35

      Years

      Prior Experience

      Genentech, Boehringer-Ingelheim

      Mr. Anicetti has more than 35 years of biopharmaceutical experience, including an extensive background leading biopharma quality organizations. Prior to joining Coherus in 2014, he was the Executive Director of Quality for Boehringer-Ingelheim’s California facility, where he was responsible for Quality, EH&S and on-site Regulatory Chemistry, Manufacturing and Control. Before BI, he was a Scientific and Regulatory Affairs Fellow with the Parenteral Drug Association.

      Before joining PDA, Mr. Anicetti spent 30 years with Genentech, holding senior leadership roles in Quality, Regulatory Affairs and Project Portfolio Management. Most recently, he was Genentech/Roche’s Vice President of Biologics Quality, with oversight of global manufacturing sites handling 10 major biotechnology products.

      Mr. Anicetti is an adjunct professor at the Keck Graduate Institute, teaching classes in Biopharmaceutical Quality and CMC Regulatory Affairs. He is a past Chair of the Parenteral Drug Association and serves on the San Francisco State University Foundation Board. Mr. Anicetti holds BA and MS degrees in biological sciences from San Francisco State University.

  • LISA M. BELL, PH.D.

    SVP, GLOBAL REGULATORY AFFAIRS

    • LISA M.
      BELL, PH.D.

      SVP, GLOBAL REGULATORY AFFAIRS

      Industry Experience

      15

      Years

      Prior Experience

      BioMarin, Facet Biotech, Genentech

      Dr. Bell joined Coherus in 2014 with more than 15 years of experience in global regulatory affairs and drug development across various therapeutic areas at leading biopharma companies. She has driven regulatory strategy of large and small molecule programs from pre-clinical through post-marketing phase, and has worked across several therapeutic areas from oncology to neurology/inflammation and rare diseases.

      Before joining Coherus, Dr. Bell served as global head of Regulatory, Pharmacovigilance, Medical Writing and Development Quality Assurance at BioMarin Pharmaceutical. During her tenure, she led the department through various drug-approval milestones. These included the regulatory advice process for initiating three, global Phase 3 programs and the approval in the U.S. and EU of Vimizim for Mucoplysacchardosis IVA, a debilitating rare disease. Other previous posts included Senior Director of Regulatory and Safety at Facet Biotech and a 10-year stint at Genentech. Among other tasks, she spearheaded the regulatory strategy for Genentech’s anti-angiogenesis franchise, leading to approvals for Avastin in non-small cell lung cancer, late stage colorectal cancer, glioblastoma and renal cell cancer.

      Dr. Bell earned her Bachelor’s (Biology) and Masters (Biotechnology) degrees from Boston University, and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

  • MICHAEL FLEMING

    SVP, COMMERCIAL STRATEGY

    • MICHAEL
      FLEMING

      SVP, COMMERCIAL STRATEGY

      Industry Experience

      26

      Years

      Prior Experience

      Elan Corporation, Genentech, GlaxoSmithKline

      Mr. Fleming, an executive biotech professional with more than 26 years of experience in the biopharmaceutical industry, joined Coherus in 2014. He has been instrumental in the launch, commercial and business development of numerous products in various therapeutic areas, including: HIV, infectious diseases, diabetes, CNS conditions, multiple sclerosis, cardiovascular and oncology. Mr. Fleming has held senior leadership or executive management team roles at several companies including Elan Corporation, Nuvelo, Inc., Genentech, GlaxoSmithKline, SmithKline Beecham and inVentiv Health.

      At Elan Corporation plc., Mr. Fleming was Senior Vice President of Commercial and Tysabri Brand with responsibility for leading the commercial organization and Elan’s efforts in the global commercial Tysabri collaboration with Biogen Idec. Prior to that role, he spent several years as a management consultant at inVentiv Health Consulting (Campbell Alliance), heading up their Western US Biotech Corporate Development Practice. Before joining inVentiv Health, Mr. Fleming was Vice President, Commercial Operations at Nuvelo, Inc. as well as Head of Hematology Marketing at Genentech where he was responsible for overseeing the U.S. Rituxan hematology/oncology commercial effort. At GlaxoSmithKline, he was the worldwide commercial strategy lead for Zofran & Supportive Care. Mr. Fleming has also held executive positions at GlaxoSmithKline Canada and its predecessor companies, including Vice President, HIV Oncology Vaccines Business Unit and Vice President, Healthcare Policy and Market Access. In this role, in addition to leading a lobbyist unit, he was responsible for developing commercial reimbursement and health economics strategy for the organization.

      Mr. Fleming earned a Microbiology Specialist Degree (BSc) at Victoria College, University of Toronto, and an MBA at the Rotman School of Business, University of Toronto.

  • MATTHEW R. HOOPER

    SVP, GENERAL COUNSEL

    • MATTHEW R.
      HOOPER

      SVP, GENERAL COUNSEL

      Industry Experience

      26

      Years

      Prior Experience

      Johnson & Johnson, Amoco, Abbott Laboratories

      Mr. Hooper joined Coherus in October 2012 as Vice President, Legal Affairs. In September 2013, he was promoted to Senior Vice President and General Counsel with responsibility for managing the company’s legal affairs worldwide. Before joining Coherus, Mr. Hooper was Of Counsel with the Life Sciences Group of Wood, Phillips, Katz, Clark and Mortimer in Chicago, where Coherus was one of his principal clients.

      Prior to Wood Phillips, Mr. Hooper served as Vice President and General Counsel for Halozyme Therapeutics, and was also in the legal departments of Scios, Inc. and its parent company, Johnson & Johnson. His roles with Scios and J&J included Senior Patent Counsel and General Counsel for Scios (at the time of J&J’s acquisition of Scios), as well as Assistant General Counsel for J&J. Mr. Hooper has also held positions in the corporate law departments of Amoco (later British Petroleum) and Abbott Laboratories.

      Mr. Hooper earned his law degree from Northwestern and his undergraduate degree in Chemistry from LaSalle University in Philadelphia. He is admitted to the bar in Illinois and California and is registered to practice before the U.S. Patent and Trademark office.

  • AARON SCHUCHART

    SVP, BUSINESS DEVELOPMENT

    • AARON
      SCHUCHART

      SVP, BUSINESS DEVELOPMENT

      Industry Experience

      25

      Years

      Prior Experience

      Novartis/Grifols, Proaltus Partners, Amgen

      Aaron Schuchart is our Senior Vice President, Business Development and Strategic Alliances.

      Prior to joining Coherus in 2014, Mr. Schuchart was Head of Business Development and Strategy for the Clinical Diagnostics unit of Novartis Corporation. From 2010 to 2013, he advised on and led portfolio planning projects, financings, and strategic transactions for venture-backed biotechnology clients as Founder and Managing Director of Proaltus Partners, LLC. From 2007 to 2010, Mr. Schuchart was Vice President of Business Development and Strategic Planning for Mendel Biotechnology. Previously, he spent nine years in positions of increasing responsibility at Amgen, the last one as Licensing Director. Mr. Schuchart began his career with ten years of general management experience in the oil and gas industry.

      Mr. Schuchart has an MBA from the Anderson School at UCLA, a BBA from Texas Tech University, is a CPA, and a Certified Licensing Professional (CLP).

board of directors

view now

scientific advisory board

view now